2024 ASCO Breakthrough
Chinese Study Finds Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is an aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival comp...
Detecting Residual Disease After Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
Although esophageal cancer in the United States is relatively rare, affecting about 22,400 people each year and making up about 1% of all cancer cases,1 the disease is common in East and Central Asia ...
Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is a rare and aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is l...
Active Surveillance May Enable Patients With Esophageal Cancer to Delay or Avoid Surgery
Although esophageal cancer in the United States is relatively rare—affecting about 22,400 people each year and making up about 1% of all cancer cases—the disease is common in East and Central Asian co...
Selpercatinib in East Asian Patients With RET Fusion–Positive NSCLC: LIBRETTO-431
Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung c...
